Nevro Corp NVRO:NYSE

Last Price$45.59NYSE Previous Close - Last Trade as of 7:00PM ET 7/01/22
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$41.66 (1)
Ask (Size)$49.51 (1)
Day Low / HighN/A - N/A
Volume332.8 K
 

View Medical Specialties IndustryPeer Comparison as of 07/01/2022

 

Nevro Corp ( NYSE )

Price: $45.59
Change: +1.76 (4.02%)
Volume: 332.8 K
7:00PM ET 7/01/2022
 
 

Silk Road Medical Inc ( NASDAQ )

Price: $38.94
Change: +2.55 (7.01%)
Volume: 215.0 K
4:00PM ET 7/01/2022
 
 

AtriCure Inc ( NASDAQ )

Price: $41.01
Change: +0.15 (0.37%)
Volume: 276.4 K
4:00PM ET 7/01/2022
 
 

Avanos Medical Inc ( NYSE )

Price: $27.74
Change: +0.40 (1.46%)
Volume: 194.0 K
7:00PM ET 7/01/2022
 
 

CareDx Inc ( NASDAQ )

Price: $22.41
Change: +0.93 (4.33%)
Volume: 618.4 K
4:00PM ET 7/01/2022
 

Read more news Recent News

Morgan Stanley Adjusts Price Target for Nevro to $55 From $74, Reiterates Equalweight Rating
9:54AM ET 6/07/2022 MT Newswires

Nevro (NVRO) has an average hold rating and price target range of $49 to $95, according to analysts polled by Capital IQ. (MT Newswires covers equity,...

JMP Securities Adjusts Price Target for Nevro to $95 From $125, Keeps Market Outperform Rating
10:16AM ET 5/26/2022 MT Newswires

Nevro (NVRO) has an average hold rating among analysts, with a price target range of $64 to $150. (MT Newswires covers equity, commodity and economic...

Citigroup Adjusts Nevro's Price Target to $68 From $78, Reiterates Buy Rating
8:56AM ET 5/17/2022 MT Newswires

Nevro (NVRO) has an average rating of hold and price targets ranging from $64 to $125, according to analysts polled by Capital IQ. (MT Newswires covers...

--Citigroup Upgrades Nevro to Buy From Neutral; Price Target is $78
7:37AM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionNevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA. View company web site for more details
Address1800 Bridge Parkway
Redwood City, California 94065
Phone+1.650.251.0005
Number of Employees804
Recent SEC Filing06/17/20224
Chairman, President & Chief Executive OfficerD. Keith Grossman
Chief Financial OfficerRoderick H. MacLeod
Chief Medical OfficerDavid Caraway
Vice President-Technical OperationsChristopher Christoforou

Company Highlights

Price Open$44.09
Previous Close$43.83
52 Week Range$39.41 - 168.19
Market Capitalization$1.6 B
Shares Outstanding35.3 M
SectorHealth Technology
IndustryMedical Specialties
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.49
Beta vs. S&P 500N/A
Revenue$387.3 M
Net Profit Margin-35.25%
Return on Equity-44.57%

Analyst Ratings as of 06/27/2022

Buy
3
Overweight
0
Hold
8
Underweight
1
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset